Last reviewed · How we verify
BGC20-0582
BGC20-0582 is a drug that targets the PD-1 receptor.
BGC20-0582 is a drug that targets the PD-1 receptor. Used for Non-small cell lung cancer, PD-L1 positive, Head and neck squamous cell carcinoma.
At a glance
| Generic name | BGC20-0582 |
|---|---|
| Sponsor | Boston Scientific Corporation |
| Drug class | PD-1 inhibitor |
| Target | PD-1 |
| Modality | Small molecule |
| Therapeutic area | Oncology |
| Phase | Phase 2 |
Mechanism of action
BGC20-0582 works by binding to the PD-1 receptor, which is a protein on the surface of immune cells. This binding blocks the interaction between PD-1 and its ligands, leading to the activation of immune cells and the enhancement of anti-tumor responses.
Approved indications
- Non-small cell lung cancer, PD-L1 positive
- Head and neck squamous cell carcinoma
Common side effects
- Pneumonitis
- Hypothyroidism
- Hyperthyroidism
Key clinical trials
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |